(Q44634053)

4 December 2017

title

Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma (English)

1 reference

4 December 2017

2

1 reference

ORCID Public Data File 2021

4 December 2017

1 reference

author name string

R Crocchiolo

1

1 reference

4 December 2017

S Fürst

3

1 reference

4 December 2017

J El-Cheikh

4

1 reference

4 December 2017

C Faucher

5

1 reference

4 December 2017

C Oudin

6

1 reference

4 December 2017

A Granata

7

1 reference

4 December 2017

R Bouabdallah

8

1 reference

4 December 2017

D Coso

9

1 reference

4 December 2017

C Chabannon

10

1 reference

4 December 2017

M Balzarotti

11

1 reference

4 December 2017

A Santoro

12

1 reference

4 December 2017

D Blaise

13

1 reference

4 December 2017

language of work or name

English

0 references

publication date

25 June 2012

1 reference

Bone Marrow Transplantation

4 December 2017

published in

1 reference

4 December 2017

volume

48

1 reference

4 December 2017

issue

2

1 reference

4 December 2017

page(s)

249-252

1 reference

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

7 January 2021

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

7 January 2021

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

7 January 2021

Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

7 January 2021

High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

7 January 2021

Bone marrow transplantation with unrelated donors: what is the probability of identifying an HLA-A/B/Cw/DRB1/B3/B5/DQB1-matched donor?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.116

7 January 2021

Identifiers

DOI

10.1038/BMT.2012.116

1 reference

4 December 2017

1 reference